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Abstract 
Background: Type 2 diabetes mellitus is an important risk factor in the development of coronary artery disease 
(CAD) and is often associated with severe disease. However, this risk is not uniform, some patients remain free of CAD 
even after many years of treatment for diabetes. The present study was aimed to identify the factors that are associ-
ated with a favorable CAD profile.
Methods: A case–control study of 76 patients with type 2 diabetes mellitus who were on treatment for more than 
10 years duration and undergoing a coronary angiogram for the evaluation of clinically suspected CAD at a tertiary 
care hospital were recruited for the study. The presence and absence of significant CAD was determined after a 
coronary angiogram. Clinical history, and anthropometric and biochemical parameters were analyzed. Insulin resist-
ance was determined by the Homeostasis Model Assessment. Multiple logistic regressions were done to find out the 
factors associated for a favorable CAD profile.
Results: The difference in HOMA-IR (2.37 ± 0.69 VS 3.77 ± 1.64, p < 0.001) and urine microalbumin (24.15 ± 32.16 
VS 82.72 ± 117.70, p = 0.004) were found to be statistically significant among those who did not have CAD when 
compared to those who had CAD. The difference in lipid profile, HbA1C, fasting blood sugar, BMI, waist hip ratio, waist 
and hip circumference was not significant. The adjusted odds ratio for insulin resistance less than 2.5 (OR 9.09, 95 % CI 
1.91–41.83, p = 0.005), females (OR 7.91, 95 % CI 1.55–40.38, p = 0.013) and microalbumin <20 mg/l (OR 4.57, 95 % CI 
1.17–17.85, p = 0.029) were independently associated with normal coronaries. The adjusted odds ratio for lipid profile, 
BMI, blood pressure and HbA1C were not significant.
Conclusions: HOMA-IR less than 2.5, microalbuminuria less than 20 mg/l and females are the factors appear to be 
associated with no apparent CAD.
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Background
Type 2 diabetes mellitus is an independent risk factor 
for coronary artery disease and often associated with 
severe and extensive disease [1]. The phenomenon for the 
development of coronary artery disease (CAD) in type 2 
diabetes mellitus is multifactorial and the known risk fac-
tors account for about 25 % of the disease [2]. Even with 
significant advances in anti-glycemic therapies, the risk 
of macrovascular complications is not reduced in type 2 
diabetes mellitus [3].
In general, individuals with type 2 diabetes mellitus 
have to be treated aggressively for better cardiovascular 
outcome. However, diabetes itself being a heterogeneous 
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disease, [4] it has been seen that development of car-
diovascular complications is not uniform in all patients 
with diabetes mellitus. Most of the diabetic populations 
are prone to get CAD in spite of conventional risk factors 
being controlled and some patients remain free of CAD 
despite many years of treatment for diabetes.
Recent rethinking has led to the conclusion that, the 
treatment for type 2 diabetes mellitus should be individu-
alized. A paradigm shift is observed in the management 
of type 2 diabetic patients towards individualized treat-
ment. A study of risk factors associated with favorable 
CAD profile will help in identifying low risk patients and 
will also help to control these factors in future genera-
tion of CAD in diabetic patients. By identifying a specific 
parameter where individualized treatment can be per-
formed light might be thrown on reducing the vascular 
complications in type 2 diabetes mellitus.
Thus the present study was designed to evaluate the 
role of insulin resistance along with other clinical mark-
ers in type 2 diabetic patients who were angiographically 
documented with and without significant CAD, and on 
treatment for diabetes for more than 10 years.
Methods
A case control study of 76 consecutive patients with type 
2 diabetes mellitus, who were on treatment for a dura-
tion of more than 10 and who underwent a coronary 
angiogram for the evaluation of clinically suspected CAD 
[Those presenting with atypical angina and Treadmill test 
(TMT)–positive] at a Kasturba Medical College hospital, 
Mangalore, India were recruited from June 2013 to Sep-
tember 2014, after obtaining the written informed con-
sent. The patients were selected randomly from a sample 
of 243 patients who participated in an ongoing cross-sec-
tional study [5].
The details of diabetic duration were obtained from 
patients through their past medical history or from pervi-
ous hospital records and from personal history of diabe-
tes. The study was restricted to a population between the 
ages of 45 and 65 years, since studies show that beyond 
65  years of age the extent and degree of CAD remains 
same in all the population [6].
From the cohort of 243 patients, 76 patients were 
found to have a diabetic duration of more than 10 years. 
38 controls and 38 cases were selected by computer gen-
erated randomization. Individuals were divided into con-
trol and cases based on the presence and absence of a 
significant CAD which was documented after a coronary 
angiogram. The presence of significant CAD was defined 
as any visible stenosis greater than 50 % on angiography 
in at least one major coronary artery [7], and those with 
stenosis <20 % or luminal irregularities in any of the epi-
cardial arteries were defined to have ‘No Apparent CAD’ 
[8]. Based on the angiographic findings, 38 patients 
were found to have CAD considered as cases and the 
remaining 38 did not have significant CAD and served as 
controls.
Type 2 diabetes mellitus was diagnosed on the basis of 
glycated hemoglobin (HbA1c) levels and fasting blood 
glucose, according to the American Diabetes Association 
criteria (all T2DM individuals had HbA1c levels >6.5  % 
and fasting blood glucose >126 mg/dl) [9].
Those patients satisfying the ADA criteria for type 2 
diabetes mellitus, who were on treatment for a duration 
of more than 10  years and those who had undergone a 
coronary angiogram were included in the study. Patients 
with known cases of chronic kidney disease, valvular 
heart disease, thyroid disorders, less than 10  years of 
diabetic duration, those who were on exogenous insulin 
administration and on steroids were excluded from the 
study. The study was conducted after obtaining the ethi-
cal approval from the Institutional Ethics Committee.
All the clinical findings were noted. Anthropometric 
measurements such as height, weight, waist and hip cir-
cumference were noted as per standard norms [10]. Body 
Mass Index (BMI) and waist hip ratio were calculated. 
Biochemical parameters such as fasting blood sugar, fast-
ing insulin, fasting lipid profile, and urine microalbumin 
were analyzed as previously described by Srinivasan et al. 
[5]. The glycated hemoglobin was analyzed by high per-
formance liquid chromatography (HPLC). The degree 
of insulin resistance was measured by the Homeostasis 
Model Assessment (HOMA 2) computerized method 
[11]. In large epidemiological studies, the use of HOMA-
IR has been shown to correlate well with gold standard 
hyper-insulinemia euglycemic glucose clamp technique 
for the measurement of insulin resistance [12]. Individu-
als were said to be insulin resistant if HOMA-IR value 
was 2.5 or above, which is considered to be the optimal 
cutoff value particularly with respect to the Indian popu-
lation [13]. In order to achieve a steady state and to avoid 
changes in insulin resistance that may occur due to acute 
stress of the disease and due to angiographic procedure, 
the blood test was done 2 weeks after the performance of 
the coronary angiogram [14].
The study population was also followed up for 1  year 
looking for any Major Adverse Cardiovascular Events 
(MACE) at 1  year. MACE is defined as cardiac death, 
nonfatal myocardial infarction, or target lesion revascu-
larization [15]. Accordingly, at the end of one-year the 
MACE rate was calculated.
Statistical analysis
Data were presented as mean  ±  SD. The categorical 
variables were represented as proportions/percentages. 
The normality assumption for continuous variables was 
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evaluated by the Kolmogorov–Smirnov test. The inde-
pendent sample t test was carried out in order to com-
pare the means between the cases and the controls. A 
multiple logistic regression analysis with the absence of 
significant CAD as a dependent variable was performed. 
The adjusted odds ratio for insulin resistance and other 
biochemical risk factors was estimated and the results 
were represented as adjusted odds ratio (OR) and 95  % 
confidence interval (95 % CI). P < 0.05 was considered to 
be statistically significant. Analysis was carried out using 
the Statistical Package for Social Sciences (SPSS Version 
16, Chicago, IL, USA).
Results
Seventy-six patients with type 2 diabetes mellitus who 
were on treatment for a duration of more than 10 years 
were analyzed in this case control study. The mean age 
of our study population was 56.61 ± 5.36. The presence 
of significant CAD was seen in 38 patients (50  %) and 
38 patients did not have significant CAD (50 %). In this 
present study, the male population of 50 (66 %) was pre-
dominantly high compared to female population of 26 
(44 %). Among the study population, 22 (58 %) males and 
16 (42  %) females did not have significant CAD and 28 
(74 %) males and 10 (26 %) females were found to have 
CAD respectively. About 15 (40  %) were hypertensive 
and 23 (60 %) did not have hypertension in those without 
CAD and 21 (55 %) were hypertensive and 17 (45 %) did 
not have hypertension in subjects presenting with CAD.
The clinical characteristics of diabetic patients with 
and without CAD are shown in Table  1. There was a 
significant difference in the mean value of HOMA-IR 
(p  <  0.001), microalbumin (p  =  0.005), fasting blood 
sugar (p  =  0.007) and ejection fraction (p  <  0.001) in 
patients with CAD when compared to patients without 
CAD (Table 1). There was no significant difference in the 
mean value of fasting lipid profile, waist circumference 
and body mass index between the two groups (Table 1).
The multiple logistic regression analysis was per-
formed with the presence/absence of significant CAD 
as the dependent variable and the following as pre-
dictive variables: HOMA-IR, hypertension, smoking, 
microalbuminuria, HbA1c, BMI, Low density lipopro-
tein- cholesterol (LDL), high density lipoprotein- cho-
lesterol (HDL), total cholesterol to HDL ratio and waist 
circumference. HOMA-IR <2.5 (OR: 9.09, 95 % CI 1.91–
41.83, p = 0.005), females (OR 7.91, 95 % CI 1.55–40.38, 
p = 0.013) and microalbumin <20 mg/l (OR: 4.57, 95 % 
CI: 1.17–17.85, p = 0.029) were independently associated 
with the absence of significant CAD. The adjusted odds 
ratio for lipid profile, BMI, hypertension and waist cir-
cumference were not significant (Table 2).
At the end of 1 year, 3 (7.9 %) out of 38 subjects with 
No Apparent CAD, and 15 (41 %) out of 38 subjects with 
CAD developed MACE (p  <  0.001). Based on HOMA-
IR levels, 18 (38 %) out 47 subjects with HOMA-IR >2.5 
developed MACE. The MACE was not observed in any of 
subjects with HOMA-IR <2.5 (p = 0.001).
Discussion
Despite their being controlled for conventional risk fac-
tors of CAD, the majority of diabetic patients have an 
early onset of coronary artery disease and the involved 
vessels show severe disease. Most of the long term com-
plications in diabetics are vascular in nature. Type 2 dia-
betic individuals are not homogenous in nature, in spite 
of many years of treatment for type 2 diabetes mellitus 
some patients remain free of CAD. Thus in the present 
Table 1 Clinical characteristics of type 2 diabetic patients with and without CAD
HOMA–IR homeostasis model assessment–insulin resistance, TC/HDL total cholesterol/high density lipoprotein ratio, LDL low density lipoprotein, HbA1c hemoglobin 
A1C
Variable Type 2 diabetic patients  
with CAD (N = 38)
Type 2 diabetic patients  
without CAD (N = 38)
p value
Duration of diabetes (years) 17.02 ± 4.38 14.50 ± 3.76 0.009
Fasting blood sugar (mg/dl) 210.87 ± 61.77 170.84 ± 63.66 0.007
Fasting Insulin (IU/µl) 22.83 ± 7.95 15.95 ± 5.26 <0.001
HOMA-IR 3.77 ± 1.63 2.37 ± 0.69 <0.001
HbA1c 9.72 ± 2.08 9.23 ± 1.69 0.261
Total cholesterol (mg/dl) 169.15 ± 64.06 165.21 ± 42.49 0.753
TC/HDL 4.26 ± 1.56 4.28 ± 1.70 0.967
LDL-C (mg/dl) 106.78 ± 51.70 102.16 ± 40.73 0.667
Microalbumin (mg/l) 82.22 ± 117.70 24.15 ± 32.61 0.004
Body mass index (kg/m2) 23.09 ± 2.54 23.33 ± 3.03 0.714
Waist circumference (cm) 86.99 ± 8.56 87.07 ± 6.73 0.965
Ejection fraction 47.84 ± 7.94 59.15 ± 3.31 <0.001
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study we wanted to find out which of these factors are 
associated with No Apparent CAD in type 2 diabetic 
patients who are on treatment for a duration of more 
than 10 years. In this population of diabetic patients who 
are on treatment for more than 10  years of duration, 
HOMA-IR <2.5, microalbumin <20  mg/l and females 
were independently associated with No Apparent CAD.
Much data suggests that insulin resistance has a cen-
tral role in atherosclerosis and is subsequently associated 
with an elevated risk of cardiovascular disease [16, 17]. 
Altered insulin signaling in endothelial cells has emerged 
as an important mechanism for the increased suscepti-
bility to cardiovascular disease [17]. Under physiologi-
cal conditions, there is a delicate and balanced release 
of relaxing factors and endothelium-derived contrac-
tion factors that are apparently imbalanced in diabetes. 
Endothelial dysfunction which develops due to this alter-
ation contributes to progressive atherosclerosis along 
with the proinflammatory state induced by insulin resist-
ance [17].
At physiological levels, insulin initiates its action by 
binding to its specific cell surface receptor present in 
liver and skeletal muscle. The interaction between insulin 
and its receptors triggers the cascade of events associated 
with multiple physiologic or pathologic processes. Upon 
binding with its ligand, a series of structural conforma-
tional changes are initiated, resulting in the activation of 
intracellular tyrosine kinases and subsequent intracel-
lular signal transduction, ultimately leading to the regu-
lation of various important physiologic functions in the 
human body.
The mechanism of action of insulin is biphasic, insu-
lin at basal state promotes a mitogenic pathway and the 
pulsatile action of insulin promotes a metabolic pathway. 
At normal physiological levels of insulin, the metabolic 
functions are mediated through the phosphatidylinositol 
(PI) 3-kinase pathway, playing a crucial role in GLUT-4 
translocation, an important mechanism of insulin action; 
on the contrary, the mitogenic action of insulin is medi-
ated through mitogen-activated protein kinase (MAPK) 
pathway, which mediates the non-metabolic, pro-inflam-
matory and proliferative effects of insulin [18].
In the case of insulin resistance, the response of tar-
get cells towards insulin is considerably diminished for 
metabolic (i.e., glucose metabolism) action, but with pre-
served mitogenic and anabolic actions. An acute rise in 
basal insulin is stimulatory, but a steady increase in insu-
lin levels attenuates the target cells for glucose metabo-
lism, through various mechanisms, by exerting its effects 
at the level of the receptor itself and at various sites out-
side the receptor as well. The constant elevated level of 
basal insulin, irrespective of its origin, usually leads to 
generalized insulin resistance [19]. The metabolic action 
of insulin is impaired while the mitogenic action is still 
ongoing. In other words, the phosphatidylinositol (PI) 
3-kinase pathway is inhibited and MAPK pathway is still 
intact leading to proliferative, fibrotic changes in vascu-
lature which explains the severity of the disease and the 
long segment disease seen in diabetic patients.
Studies have been reported where long term cardiovas-
cular complications could be predicted by the measure 
of insulin resistance [20, 21] and subsequent study has 
also shown that elevated insulin resistance is also asso-
ciated with severity of CAD in type 2 diabetes mellitus 
[5]. In the present study, low level of HOMA-IR is inde-
pendently associated with favorable CAD profile in long 
standing diabetic population.
Insulin resistance which is one of the components of 
metabolic syndrome has shown to be relatively constant in 
type 2 diabetes mellitus whereas all the other conventional 
Table 2 Logistic regression analysis for predicting favorable CAD profile in type 2 diabetic patients who are on treatment 
for more than 10 years of duration
TC/HDL total cholesterol/high density lipoprotein ratio, LDL low density lipoprotein
Variable Wald B Adjusted odds ratio p value 95 % CI
Insulin resistance <2.5 8.03 2.20 9.09 0.005 1.97–41.83
Females 6.18 2.06 7.91 0.013 1.55–40.38
Microalbumin <20 mg/l 4.79 1.52 4.57 0.029 1.17–17.85
Duration of diabetes (years) 2.05 0.11 1.12 0.152 0.95–1.31
Fasting blood glucose (mg/dl) 2.20 0.008 1.00 0.137 0.99–1.01
TC/HDL 0.001 −0.03 0.97 0.969 0.21–4.35
LDL-C (mg/dl) 0.54 0.50 1.65 0.461 0.43–6.36
Hypertension 1.07 0.66 1.94 0.300 0.55–6.87
Age 0.03 −0.011 0.98 0.856 0.87–1.11
Body mass index (kg/m2) 0.97 0.81 2.26 0.323 0.44–11.38
Waist circumference (cm) 0.25 0.42 1.52 0.616 0.29–7.99
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risk factors changes over a period of time. Even the United 
Kingdom Prospective Diabetes study over 6 years of con-
ventional treatment for type 2 diabetes has shown that 
insulin sensitivity, the reciprocal of insulin resistance being 
constant with 62, 60 and 62 % at 0, 1 and 6 years [22–24]. 
Thus in clinical practice it is important to look for insulin 
resistance and identify the individuals with high insulin 
resistance in the beginning itself as insulin resistance is 
known to predict long term complications.
Gender is also known to be one of the additional risk 
factor associated with cardiovascular disease. The mean 
HOMA-IR in type 2 diabetic females without CAD was 
2.73 ± 0.68 and 2.11 ± 0.59 in type 2 diabetic males with-
out CAD. Vonbank et al. has shown that insulin resistance 
in females is associated with metabolic syndrome but not 
with angiographically determined CAD [25]. Despite of 
having HOMA-IR value greater than 2.5, similarly in our 
study we found that type 2 diabetic females are known to 
be associated absence coronary atherosclerosis.
Microalbumin, a risk factor for cardiovascular disease 
is known to be associated with a coronary endothelial 
dysfunction. The studies have shown that the coronary 
endothelial dysfunction correlates with increasing levels 
of microalbumin in type 2 diabetic patients [26]. How-
ever, several cross sectional and longitudinal studies have 
shown that the insulin resistance is independently asso-
ciated with development of microalbuminuria in type 2 
diabetes mellitus [27, 28].
Since insulin resistance precedes much before than 
microalbuminuria in type 2 diabetes mellitus, it is pos-
sible that an elevated insulin resistance contributes to 
the development of microalbuminuria in type 2 diabetes 
mellitus. In our study we found that the mean microalbu-
min levels was 18.62 ± 11.28 in patients with HOMA-IR 
less than 2.5, and thus lower levels of microalbuminuria 
was found to be associated with No Apparent CAD in 
long standing diabetes.
The microvascular complications are normally seen 
in long standing diabetes. There is enough evidence 
to prove that intense glycemic control has resulted in 
microvascular benefit [29] in long standing diabetes, but 
the ACCORD trial has shown that intense glycemic con-
trol did not yield protection against CAD particularly in 
those with long standing diabetes [30]. In a cross-sec-
tional study, severe vascular changes in coronary arteries 
were observed in more than 5 years of type 2 diabetes and 
an elevated insulin resistance accounted for this most of 
the cardiovascular burden in more than 5 years of type 2 
diabetes mellitus [31]. Thus the macrovascular complica-
tions are time dependent should be addressed at a much 
earlier stage of type 2 diabetes mellitus.
A recent observation by recent Kim et al., where Intra-
vascular Ultrasound (IVUS) a gold standard method to 
identify any vulnerable plaques in coronary arteries, was 
used to study the coronary artery remodeling [32]. The 
findings from the study reveals that, those with HOMA-
IR >2.5 had positive coronary artery remodeling when 
compared to those HOMA-IR <2.5 [32]. Thus individu-
als with high HOMA-IR (HOMA-IR >2.5) are suscep-
tible to develop future cardiovascular events. In this 
present study we observed that, subjects with HOMA-IR 
<2.5 did not develop any form of adverse cardiac events 
at the end of one year even, when compared to those 
with HOMA-IR >2.5 which is in lines with findings from 
Kim et al.
The unique evolution of insulin resistance in type 2 
diabetes mellitus will help us in identifying the patients 
with high HOMA-IR in the beginning itself. Since low 
levels of HOMA-IR is associated with No Apparent 
CAD in long standing diabetes, the patients with high 
IR should be managed aggressively in the initial phase 
of diabetes. Maintaining a normal blood glucose level in 
type 2 diabetics by use of either oral medications or insu-
lin will only fulfill the guideline requirements and will 
not achieve any long term benefits. It will not decrease 
insulin resistance or hyperinsulinemia that is present in 
these patients. The ultimate goal should be to target the 
patients with high HOMA-IR at the very beginning and 
encourage them to adopt radical life style modifications 
and thus disrupt the cascade of insulin resistance leading 
to CAD.
Limitations
The limitation of the study is a small sample size and a 
single center study. Another limitation of the study is its 
study design. Ideally, prospective studies need to be car-
ried out to determine the role of insulin resistance in type 
2 diabetic patients without CAD. Long term follow-up 
with HOMA-IR measured at the onset of the disease and 
compared with angiographic findings after a few years 
along with other known risk factors might allow us to 
evaluate the role of each factor associated with a favora-
ble CAD profile. The hyper-insulinemia euglycemic glu-
cose clamp technique is said to be the gold standard for 
the measurement of insulin resistance/hyperinsulinemia 
but due its practical inconvenience, HOMA-IR index was 
used which has shown a good correlation with hyper-
insulinemic euglycemic clamp test. Intravascular ultra-
sound (IVUS) is to be a gold standard method to identify 
vulnerable plaques, but in this present study the Coro-
nary Angiogram was used to define No Apparent CAD, 
where a discrepancy in the results might be possible. 
However, it still remains unclear what morphological fea-
tures will best predict plaque rupture and which diagnos-
tic technologies would reliably predict the pathological 
and clinical courses of a vulnerable plaque.
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Conclusion
The results of our study indicates that HOMA-IR less 
than 2.5 microalbuminuria less than 20 mg/l and females 
appears to be the factors associated with a favorable CAD 
profile even with the absence of comparable lipid and gly-
cemic parameters in type 2 diabetes mellitus in patients 
on treatment for a duration of more than 10 years.
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